CH505 TF chTrimer

Developed for: HIV infectious disease
Investigated by: National Institute of Allergy and Infectious Diseases (NIAID) · Duke University · Access to Advanced Health Institute (AAHI) · Department of Health and Human Services · Henry M. Jackson Foundation for the Advancement of Military Medicine · Janssen Vaccines & Prevention B.V.
+4 more
· Makerere University Walter Reed Project · National Institutes of Health (NIH) · U.S. Army Medical Research and Development Command · Walter Reed Army Institute of Research (WRAIR)

20232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06680479	Apr 2025 → Apr 2027	—	National Institute of Allergy and Infectious Diseases (NIAID)	Suspended	No outcome recorded
Phase 1	NCT06267872	Oct 2024 → Dec 2025	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Withdrawn	No outcome recorded
Phase 1	NCT06205056	Jan 2024 → Dec 2025 overdue	HIV infectious disease	U.S. Army Medical Research and Development Command	Recruiting	No outcome recorded
Phase 1	NCT04915768	Jan 2023 → Jul 2025	HIV infectious disease	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Every value below carries the sentence it was read from. 5 sources stand behind the page.

Field	Value	Cited text
Known as	CH505 TF chTrimer	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06680479 ↗ 3 NCT06205056 ↗ NCT06267872 ↗ NCT04915768 ↗
Known as	CH505 TF chimeric (ch) Trimer	“HVTN 300 is a first-in-human, open-label Phase 1 study evaluating the safety and immunogenicity of a CH505 TF chimeric (ch) Trimer adjuvanted with 3M-052-AF (a TLR7/8 agonist) + Alum.” PMID 41959788 ↗ Apr 2026
Modality	Vaccine	“CH505 TF chTrimer vaccine” NCT04915768 ↗
Route	Intramuscular	“All products will be administered by intramuscular (IM) injection into the same quadriceps muscle at each product administration visit.” NCT06205056 ↗